Detailed Mechanism Funding and Narrative

Details for Mechanism ID: 18453
Country/Region: Ukraine
Year: 2016
Main Partner: New Partner
Main Partner Program: NA
Organizational Type: Unknown
Funding Agency: USAID
Total Funding: $0 Additional Pipeline Funding: N/A

NOTE: PEPFAR no longer creates activity narratives for each mechanism. In their place, PEPFAR has begun releasing mechanism specific targets that reveal the achievements and programs that are expected of the funding. If available for this mechanism, these targets are presented below.

Mechanism Allocation by Budget Code for Selected Year
Treatment: ARV Drugs (HTXD) $0
Mechanism Target Information

Since COP2014, PEPFAR no longer produces narratives for every mechanism it funds. However, PEPFAR has now included performance targets or indicator information for each mechanism based on the Monitoring, Evaluation, and Reporting (MER) system. The MER guidance is available on PEPFAR's website https://www.pepfar.gov/reports/guidance/. Note that COP years 2014-2015 were under a previous version of the MER system and the indicators and definitions may have changed as of the new 2.0 guidance.

MER Indicator MER description Target Fiscal Year Target
TX_CURR Aggregated Age/Sex: 15+ Female 2017 17,448
TX_CURR Aggregated Age/Sex: 15+ Male 2017 21,325
TX_CURR Number of adults and children receiving antiretroviral therapy (ART) 2017 38,766
TX_CURR Sum of Aggregated Age/Sex 15+ 2017 38,773
TX_CURR Sum of Aggregated Age/Sex disaggregates 2017 38,773
TX_NEW Aggregated Grouping by Age/Sex: 15+ Female 2017 9,364
TX_NEW Aggregated Grouping by Age/Sex: 15+ Male 2017 11,432
TX_NEW Number of adults and children newly enrolled on antiretroviral therapy (ART) 2017 20,786
TX_NEW Sum of Aggregated Age/Sex disaggregates 2017 20,796
TX_PVLS Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months 2017 33,095
TX_PVLS Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months 2017 25,833
TX_PVLS Numerator Aggregated Age/Sex: 15+ Female 2017 11,632
TX_PVLS Numerator Aggregated Age/Sex: 15+ Male 2017 14,197
TX_PVLS Numerator: Indication: Routine 2017 25,830
TX_PVLS_den Denominator Aggregated Age/Sex: 15+ Female 2017 14,895
TX_PVLS_den Denominator Aggregated Age/Sex: 15+ Male 2017 18,206
TX_PVLS_den Denominator: Indication: Routine 2017 33,003
TX_RET Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 6,900
TX_RET Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 8,423
TX_RET Number of adults and children who are still alive and on treatment at 12 months after initiating ART 2017 15,321
TX_RET Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up 2017 18,046
TX_RET_den Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 8,133
TX_RET_den Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 9,912